The Government to Directly Supply Induced Pluripotent Stem Cell Lines for Clinical Research
National Stem Cell Bank to Supply KNIH01 Starting June 30
Clinical-Grade Cell Lines for Cell Therapy Produced in GMP Facilities
"Supporting Advanced Biopharmaceutical Research Including Artificial Blood"
The National Stem Cell Bank of the National Institute of Health under the Korea Disease Control and Prevention Agency announced on June 12 that it will begin the actual supply (distribution) of induced pluripotent stem cell lines for use as raw materials in cell therapy products starting from June 30, in order to support domestic stem cell and regenerative medicine research as well as the development of stem cell therapies.
The induced pluripotent stem cell lines to be supplied this time are clinical-grade cell lines produced in facilities adhering to Good Manufacturing Practice (GMP) standards. Researchers can utilize these cell lines for the development of cell therapies and clinical research. For the clinical research-use KNIH01 induced pluripotent stem cell line, four vials will be provided at the initial distribution, with additional vials available upon mutual agreement. Currently, 100 vials are secured as distribution resources, and additional production will be carried out continually to maintain this supply at a certain level.
National Stem Cell Bank Yearly Stem Cell Resource Distribution Status. National Institute of Health
View original imageThe clinical-grade induced pluripotent stem cell lines to be supplied this time are derived from the peripheral blood of cell donors and produced in accordance with international quality standards and the Standard Operating Procedures of the National Stem Cell Bank, making them suitable as source cells for the development of various cell therapies. To broadly support stem cell research for diverse purposes, the National Stem Cell Bank will also begin the distribution of three newly established research-use induced pluripotent stem cell lines.
The National Institute of Health expects that the launch of this distribution by the National Stem Cell Bank will alleviate the burden on researchers of having to produce cells themselves, and will enable significant savings in time, effort, and substantial costs required for the development of therapies.
Further details on the distribution will be provided on the National Institute of Health website later this month.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Wonho Kim, Director of the Division of Chronic Disease Convergence Research, stated, "By distributing clinical-grade stem cell lines, we can overcome limitations such as cost and time competitiveness, and accelerate advanced biopharmaceutical development research—including artificial blood. I hope many researchers will actively make use of these resources."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.